In reproductive medicine, GLP-1 receptor agonists were initially conceptualised in early integrative and narrative studies primarily as metabolic agents that indirectly improved ovulatory function and fertility by facilitating weight loss, insulin sensitisation, and systemic endocrine normalisation in obese women and patients with PCOS. This evidence concerns the gene GLP1R and polycystic ovary syndrome.